Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3"
design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in
combination with irinotecan.